Hengrui invested nearly 100 million products and was approved to be listed in Germany

On January 11, Hengrui pharmaceutical announced that its subsidiary, cadiasun Pharma GmbH, had recently received an approval letter from the German Federal Institute of drugs and medical devices, which approved the listing application of the company's iodimethanol injection in Germany The drug is an X-ray contrast agent, which is suitable for cardiovascular angiography, cerebral angiography (routine), peripheral arteriography (routine), excretory urography and computed tomography (CT) in adults It can make abnormal structures or lesions develop to distinguish healthy tissues and pathological tissues Other indications include myelography and gastrointestinal (oral and rectal) examination of the lumbar, thoracic and cervical vertebrae, as well as cardiography, excretory urography, CT enhancement and upper gastrointestinal examination in children Ioxatrol injection is developed by Norwegian naikoming Pharmaceutical Co., Ltd with the drug name of idodixanol injection and the trade name of Visipaque The drug was first listed in Sweden, Britain, Switzerland and other European countries in 1994 At present, it has been listed in China, the United States, Japan, France and other countries and regions Upon inquiry, similar products are sold in Turkey, Russia, Serbia and other countries In addition to Hengrui pharmaceutical, Beijing Beilu Pharmaceutical Co., Ltd and Yangtze River Pharmaceutical Co., Ltd have been approved to market similar products According to the IMS database, in 2017, the global sales volume of iqsa injection was about 489 million US dollars, the sales volume in Europe was about 135 million US dollars, and the sales volume in China was about 173 million US dollars Up to now, the company has invested about 90.21 million yuan in the R & D project of the product The full text of the announcement is as follows: